Previous 10 | Next 10 |
Cupertino, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...
ORLANDO, FL / ACCESSWIRE / January 25, 2023 / RedChip Companies is pleased to announce its CEO, Dave Gentry, was recently welcomed as a member of the Forbes Business Council. The Forbes Business Council committee invited Gentry to join the elite group of business leaders in recognition of his p...
CUPERTINO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...
- Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 - Brilaroxazine is a serotonin/dopamine modulator with a differentiated pharmacological and safety profile CUPERTINO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Reviva P...
- RP1208 is in preclinical development for the potential treatment of depression and obesity – - Composition of matter patents for RP1208 have been granted in key markets around the world including the United States, Europe, China, and Japan – CUPERTINO, Cali...
Reviva Pharmaceuticals press release ( NASDAQ: RVPH ): Q3 GAAP EPS of -$0.18. As of September 30, 2022, the Company’s cash totaled approximately $23.2 million compared to approximately $29.7 million as of December 31, 2021. For further details see: Reviva ...
- Over 30% enrollment in ongoing global, pivotal Phase 3 RECOVER trial - - Topline data for Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia still expected mid-2023 - - $23.2 Million in Cash as of September 30, 2022 - CUPERTINO, Calif., Nov. 14, 202...
Penny stocks are shares of companies trading below $5 per share. But these cheap stocks aren’t “lotto tickets,” unlike what popular opinion might make you think. Sure, can you get lucky trading penny stocks like playing roulette? Of course, but that can also go ...
Reviva Pharmaceuticals ( NASDAQ: RVPH ) announced Monday that the U.S. enrollment in its pivotal global Phase 3 trial for lead candidate brilaroxazine in schizophrenia had exceeded 30%, and patient recruitments in Asia are expected next month. The RECOVER trial is designed...
- Enrollment ongoing at multiple sites in the US and Europe; site initiation in Asia expected in November 2022 - - Enrollment on pace, with over 30% enrolled in the United States - - Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023...
News, Short Squeeze, Breakout and More Instantly...
Reviva Pharmaceuticals Holdings Inc. Company Name:
RVPH Stock Symbol:
NASDAQ Market:
Reviva Pharmaceuticals Holdings Inc. Website:
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also been granted in k...
2024-06-11 08:15:03 ET H.C. Wainwright analyst issues BUY recommendation for RVPH on June 11, 2024 06:40AM ET. The previous analyst recommendation was Buy. RVPH was trading at $1.45 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...